Ted W. Love - Mar 1, 2022 Form 4 Insider Report for Global Blood Therapeutics, Inc. (GBT)

Role
President and CEO, Director
Signature
/s/ Miguel Carrillo, Attorney-in-Fact
Stock symbol
GBT
Transactions as of
Mar 1, 2022
Transactions value $
-$100,405
Form type
4
Date filed
3/3/2022, 07:51 PM
Previous filing
Feb 3, 2022
Next filing
May 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBT Common Stock Award $21.3K +839 +0.11% $25.37 790K Feb 28, 2022 Direct F1
transaction GBT Common Stock Options Exercise +9.45K +1.2% 799K Mar 1, 2022 Direct F2
transaction GBT Common Stock Tax liability -$122K -4.07K -0.51% $29.87 795K Mar 1, 2022 Direct F3
holding GBT Common Stock 102K Mar 1, 2022 By Trust 1
holding GBT Common Stock 102K Mar 1, 2022 By Trust 2
holding GBT Common Stock 102K Mar 1, 2022 By Trust 3
holding GBT Common Stock 2.5K Mar 1, 2022 By Daughter
holding GBT Common Stock 2.5K Mar 1, 2022 By Daughter

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBT Restricted Stock Units Options Exercise $0 -9.45K -14.29% $0.00 56.7K Mar 1, 2022 Common Stock 9.45K Direct F2, F4
transaction GBT Restricted Stock Units Award $0 +72.9K $0.00 72.9K Mar 1, 2022 Common Stock 72.9K Direct F2, F5
transaction GBT Restricted Stock Units Award $0 +72.9K $0.00 72.9K Mar 1, 2022 Common Stock 72.9K Direct F2, F6
transaction GBT Stock Option (Right to buy) Award $0 +118K $0.00 118K Mar 1, 2022 Common Stock 118K $29.87 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F3 Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 9,445 shares of Common Stock underlying the Reporting Person's RSUs.
F4 The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
F5 The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
F6 The shares of Common Stock underlying the RSUs vest in two installments, if at all, based on (i) the Issuer's total shareholder return percentile ranking relative to the companies in the NASDAQ Biotechnology Index for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date, and (ii) the percentage of patient share relative to a comparator group for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
F7 The shares of Common Stock underlying the stock option vest in 16 equal quarterly installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.